| Annual · values | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|
| Gross Margin | 77.16% | 78.06% | 79.17% | 80.93% | 81.82% | 82.64% | 73.69% |
| Operating Margin | 24.00% | 26.70% | 32.99% | 27.45% | 28.66% | 10.63% | -2433.76% |
| EBITDA Margin | 26.92% | 26.74% | 33.08% | 27.54% | 28.79% | 10.88% | -2427.17% |
| Net Margin | 18.27% | 20.36% | 22.14% | 41.44% | 11.33% | -23.13% | -2535.06% |
| Current Ratio | 3.60 | 3.31 | 2.75 | 5.07 | 5.29 | 1.95 | 1.58 |
| Quick Ratio | 3.58 | 3.27 | 2.72 | 5.02 | 5.21 | 1.93 | 1.53 |
| Debt / Equity | 0.19 | 0.27 | 0.41 | 0.48 | 1.03 | 2.00 | -0.23 |
| ROE | 18.24% | 22.07% | 27.59% | 45.05% | 18.55% | -38.02% | 35.94% |
| ROA | 12.48% | 14.56% | 15.88% | 26.93% | 7.98% | -8.65% | -142.43% |
| Asset Turnover | 0.68 | 0.72 | 0.72 | 0.65 | 0.70 | 0.37 | 0.06 |
| Book Value / Share | 14.86 | 11.39 | 7.74 | 6.59 | 3.15 | 3.77 | -54.37 |
Harmony Biosciences Holdings, Inc. is a commercial-stage pharmaceutical company focused on the development and commercialization of therapies for neurological disorders. Its lead product, WAKIX, is a molecule with a novel mechanism of action that increases histamine signaling in the brain by binding to H3 receptors, primarily targeting conditions such as narcolepsy and cataplexy. The company operates in the health technology sector, specifically within pharmaceuticals, providing treatments that address unmet needs in sleep-wake disorders and related neurological conditions. WAKIX has received approvals for expanded indications, including cataplexy in pediatric patients, broadening its therapeutic reach. Harmony Biosciences Holdings, Inc. emphasizes innovative solutions in this specialized market, supporting patients through targeted pharmacotherapies. Founded in 2017 and headquartered in Plymouth Meeting, Pennsylvania, the company plays a key role in advancing treatments for rare and debilitating neurological diseases.